Navigation Links
PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
Date:11/2/2009

INCLINE VILLAGE, Nev., Nov. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it closed on its previously disclosed $300 million securitization transaction intended to monetize certain of its antibody humanization patents and royalties. Morgan Stanley & Co. Incorporated acted as sole initial purchaser for the securitization.

Under the terms of the securitization transaction, PDL sold to QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary of PDL, certain rights under its non-exclusive license agreements with Genentech, Inc., a wholly-owned subsidiary of Roche Holding, Ltd., including the right to receive 60% of the royalties from sales of Avastin® (Bevacizumab), Herceptin® (Trastuzumab), Lucentis® (Ranibizumab) and Xolair® (Omalizumab) and from sales of future products, if any, for which Genentech may take a license under the related agreements with Genentech.

QHP issued $300 million in aggregate principal amount of its QHP PhaRMA(SM) Senior Secured Notes due 2015 (the "Notes") in a non-registered offering pursuant to Rule 144A. The Notes bear an interest rate of 10.25%. The royalties and other payments, if any, that QHP will be entitled to receive under the agreements with Genentech, together with any funds made available from certain accounts of QHP, will be the sole source of payment of principal of, and interest and premium on, the Notes, which are secured by a continuing security interest granted by QHP in its rights to receive payments under such agreements and all of its other assets and a pledge by PDL of its equity ownership interest in QHP. The Notes may be redeemed at any time prior to maturity, in whole or in part, at the option of QHP at a make-whole redemption price.

PDL intends to use a sizable portion of the net offer
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
2. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
3. Helix BioPharma Corp. Announces Fiscal 2009 Results
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
9. PDL BioPharma Completes October 1 Special Dividend Payment
10. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 “Due ... cane,” said an inventor, from Gurnee, Ill. “While using the ... could be and I thought there needed to be a ... He invented the SPIKE BLOCK. , The SPIKE BLOCK offers ... doing so, it would help to reduce injuries and damage ...
(Date:11/22/2014)... In order to provide better services, LunaDress has updated ... The business knows that a suitable cocktail party dress is ... Now, the party dresses supplier’s high quality items are offered ... company in fashion industry, LunaDress understands that it is not ... it always raises the professional level and innovation ability. The ...
(Date:11/22/2014)... 22, 2014 "My friend went in ... by the machine," said an inventor from Cambria Heights, ... go back a second time because the first results ... She developed the patent-pending MAMO EASY to offer a ... design saves the patient from the pain normally involved ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2
... The Health Coalition on Liability and Access released a ... on the state and federal level. The report detailed ... passed laws limiting non-economic damages, while also acknowledging the ... to be enacted and is unlikely in the 111th ...
... are many targets now for interfering with the process , , ... from infected to uninfected immune system T-cells has been captured ... could lead to new ways to block the transmission of ... have focused on free- roaming viruses, but this study shows ...
... Test drives of the Simulated Impaired Driving Experience(R), (SIDNE(R)), ... be attending the Lifesavers conference at the Gaylord Opryland ... 30 and 31. The Lifesavers Conference is a national ... injuries on our nation,s roadways. "We are excited to ...
... Urged to Register with Safe and Well WASHINGTON, March 27 ... North Dakota and Minnesota today to staff shelters that will be ... levees as it rises to record heights. Projections are that the ... feet above flood stage, and the National Weather Service reports water ...
... 27 Zydus Pharmaceuticals announced today that it has ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... This product is available for immediate shipment.Topiramate tablets ... years old or older with partial onset or primary ...
... NYU School of Medicine have been named Early Career ... honorees, Iannis Aifantis, Ph.D. associate professor of pathology, co-director ... Cancer Institute and Jeremy S. Dasen Ph.D., assistant professor ... are among 50 of the nation,s top scientists being ...
Cached Medicine News:Health News:HCLA Releases Report on Status of Medical Liability Reform 2Health News:Scientists Capture HIV Transfer Among T-Cells on Video 2Health News:Innocorp, ltd. to Attend Lifesavers Conference 2Health News:Red Cross Readies Shelters As Flood Waters Threaten to Top Levees 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 3
... CARDIAC proBNP assay is a rapid and accurate ... reader system assisting the diagnosis and assessment of ... is both speed and accuracy profit ... CARDIAC proBNP assay = 12 minutes. In emergency ...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
Intermittent catheter...
... to a new dimension in vitreoretinal ... tool composed of purified perfluoro-n-octane, you ... Perfluoron is ideal for managing retinal ... retinal tears and trauma. , ,Certified ...
Medicine Products: